Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia

John Kim Choi; Paul E Mead

doi:10.1016/j.cll.2021.03.013

Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia

Clin Lab Med. 2021 Sep;41(3):485-495. doi: 10.1016/j.cll.2021.03.013. Epub 2021 Jul 1.

Authors

John Kim Choi¹, Paul E Mead²

Affiliations

¹ Division of Laboratory Medicine, The University of Alabama at Birmingham, WP P230N, 619 19th Street South, Birmingham, AL 35249-7331, USA. Electronic address: johnchoi@uabmc.edu.
² Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, D4026G, Mailstop 342, Memphis, TN 38105, USA.

PMID: 34304777
DOI: 10.1016/j.cll.2021.03.013

Abstract

Minimal residual disease detection provides critical prognostic predictor of treatment outcome and is the standard of care for B lymphoblastic leukemia. Flow cytometry-based minimal residual disease detection is the most common test modality and has high sensitivity (0.01%) and a rapid turnaround time (24 hours). This article details the leukemia associated immunophenotype analysis approach for flow cytometry-based minimal residual disease detection used at St. Jude Children's Research Hospital and importance of using guide gates and back-gating.

Keywords: B lymphoblastic leukemia; B-ALL; LAIP; Leukemia-associated immunophenotype; MRD; Minimal residual disease.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Child
Flow Cytometry
Humans
Immunophenotyping
Laboratories*
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma*